GlobeNewswire Clinical StudiesOriginal article
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
Phase 3XanamemPositive
AI Analysis
Summary
Xanamem (emestedastat) proof-of-concept trial data demonstrating anti-depressant activity was published in the British Journal of Psychiatry. The ongoing pivotal Phase 3 trial is progressing toward final results expected in November 2026.
Clinical Trial Data
Phase
3
Outcome Details
Proof-of-concept trial demonstrating anti-depressant activity published; pivotal trial progressing toward final results
Importance:6/10
Sentiment:
0.60
Alzheimer's diseasePhase 3Clinical trialPublicationAnti-depressant activity
Read the original article
Published by GlobeNewswire Clinical Studies on July 20, 2026 12:51 PM